Skip to main content

Advertisement

SpringerLink
Log in

Second-line and subsequent therapy for ovarian carcinoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Ovarian carcinoma continues to be the leading cause of death among gynecologic malignancies. Paclitaxel and platinum chemotherapy is still the treatment of choice after primary debulking surgery. Salvage chemotherapy with several single agents has only modest activity and does not prolong survival of patients with relapsed ovarian carcinoma. An intense search has been made for novel approaches to treatment of ovarian cancer, and several new treatments, such as immunotherapy and gene therapy, show promise. Newer combination chemotherapy regimens and molecularly targeted therapy need to be developed. High-dose chemotherapy with autologous stem-cell transplantation appears to benefit selected groups of patients and is still investigational. Whole abdominal radiotherapy for relapsed microscopic disease should be studied in prospective randomized trials. Women with advanced ovarian carcinoma should continue to be encouraged to participate in welldesigned clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Thigpen JT: Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000, 27:11–16.

    PubMed  CAS  Google Scholar 

  2. Blackledge G, Lawton F, Redman C, et al.: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989, 59:650–653.

    PubMed  CAS  Google Scholar 

  3. Markman M, Hoskins W: Responses to salvage therapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992, 10:513–514.

    PubMed  CAS  Google Scholar 

  4. Rose PG, Fusco N, Fluellen L, et al.: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16:1494–1497. This seminal publication documents the role for retreatment of patients with previously effective chemotherapy who are more than 12 months from effective first-line therapy.

    PubMed  CAS  Google Scholar 

  5. Berek JS, Bertelson K, du Bois A, et al.: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999, 10(suppl 1):S87-S92.

    Article  Google Scholar 

  6. Boente MP, Chi DS, Hoskins WJ: The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998, 25:326–334. This article confirms a role for secondary cytoreductive surgery prior to salvage chemotherapy.

    PubMed  CAS  Google Scholar 

  7. Rose PG: Surgery for recurrent ovarian cancer. Semin Oncol 2000, 27(suppl 7):17–23.

    PubMed  CAS  Google Scholar 

  8. Schray MF, Martinez A, Howes AE, et al.: Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol 1988, 6:1433–1439.

    PubMed  CAS  Google Scholar 

  9. Sedlacek TV, Spyropoulos P, Cifaldi R, et al.: Salvage therapy for ovarian carcinoma using whole abdomen radiation therapy [abstract]. Proc ASCO 1997, 16:a1263.

    Google Scholar 

  10. Wong R, Milosevic M, Sturgeon J, et al.: Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol. Int J Radiat Oncol Biol Phys 1999, 45:657–665.

    Article  PubMed  CAS  Google Scholar 

  11. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide in stage III ovarian cancer. N Engl J Med 1996, 335:1950–1955.

    Article  PubMed  CAS  Google Scholar 

  12. Alberts DS: Treatment of refractory and recurrent ovarian cancer. Semin Oncol 1999, 26(suppl 1):8–14.

    PubMed  CAS  Google Scholar 

  13. Sugiyama T, Kumagai S, Nishida T, et al.: Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Res 1998, 18(4B):837–2842.

    Google Scholar 

  14. Markman M: Weekly paclitaxel in the management of ovarian cancer. Semin Oncol 2000, 27(suppl 7):37–40.

    PubMed  CAS  Google Scholar 

  15. Rosenberg P, Andersson H, Boman K, et al.: A randomized multicenter study of single agent paclitaxel given weekly versus every three weeks to patients with ovarian cancer previously treated with platinum therapy [abstract]. Proc ASCO 1999, 18:368a.

    Google Scholar 

  16. Kaern J, Trope CG, Baekelandt M, et al.: Phase II trial of weekly single agent paclitaxel in platinum and paclitaxel refractory ovarian cancer [abstract]. Proc ASCO 2001, 20:203a. A prime example of how chemotherapy schedule and dose can have an impact on results.

    Google Scholar 

  17. Markman M, Kennedy A, Sutton G, et al.: Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998, 70:272–274.

    Article  PubMed  CAS  Google Scholar 

  18. Sorensen P, Hoyer M, Jakobsen A, et al.: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001, 81:58–62.

    Article  PubMed  CAS  Google Scholar 

  19. Burger RA, DiSaia PJ, Roberts JA, et al.: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999, 72:148–153.

    Article  PubMed  CAS  Google Scholar 

  20. Sugiyama T, Nishida T, Ookura N, et al.: Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer [abstract]? Proc ASCO 1997, 16:1347a.

    Google Scholar 

  21. Gordon AN, Fleagle JT, Guthrie D, et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312–3322.

    PubMed  CAS  Google Scholar 

  22. Bertucci F, Viens P, Delpero JR, et al.: High dose melphalanbased chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplantation 2000, 26:61–67.

    Article  PubMed  CAS  Google Scholar 

  23. Stiff PJ, Veum-Stone J, Lazarus HM, et al.: High dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000, 133:504–515. This important report concerns the controversial approach of using high-dose chemotherapy in patients with ovarian cancer. It is primarily helpful in identifying patients who would not benefit from such an approach.

    PubMed  CAS  Google Scholar 

  24. Bojko P, Scheulen ME, Hilger R, et al.: High dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 2001, 127:243–250.

    Article  PubMed  CAS  Google Scholar 

  25. Cook S, Penson R, Duska L, et al.: Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high dose chemotherapy in women with recurrent ovarian cancer. Gynecol Oncol 2000, 77:48–54.

    Article  PubMed  CAS  Google Scholar 

  26. Donato ML, Aleman AS, Gershensen DM, et al.: Long term results of 102 patients with advanced ovarian cancer treated with high dose chemotherapy [abstract]. Proc ASCO 2001, 20:204.

    Google Scholar 

  27. Cure H, Battista C, Guastalia J, et al.: Phase III randomized trial of high dose chemotherapy and peripheral blood stem cell support as consolidation in patients with responsive low burden advanced ovarian cancer: preliminary results of a GINECO/FNCLCC/SFGM-TC study [abstract]. Proc ASCO 2001, 20:204a.

    Google Scholar 

  28. Donato ML, Champlin RE, Wharton JT, et al.: Intensive-dose ifosfamide and etoposide with filgastrim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer. Eur J Gynaecol Oncol 2000, 21:241–244.

    PubMed  CAS  Google Scholar 

  29. Song K, Cowan KH, Sinha B: In vivo studies of adenovirus mediated gene therapy for cis-platinum resistant human ovarian tumor xenografts. Oncol Res 1999, 11:153–159.

    PubMed  CAS  Google Scholar 

  30. Wen S, Mahavni V, Quijano E, et al.: Evidence of p53 gene transfer and pts biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild type p53 [abstract]. Proc ASCO 2001, 20:213a. This study using p53 gene therapy shows exciting preliminary results.

    Google Scholar 

  31. Tait DL, Obermiller PS, Hatmaker AR, et al.: Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999, 5:1708–1714.

    PubMed  CAS  Google Scholar 

  32. Hasenburg A, Tong X-W, Rojas-Martinez A, et al.: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000, 7:839–852.

    Article  PubMed  CAS  Google Scholar 

  33. Hung MC, Hortbobagyi GN, Ueno NT: Development of clinical trial of gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 2000, 465:171–180.

    Article  PubMed  CAS  Google Scholar 

  34. Ueno NT, Bartholomeusz C, Hermann JL, et al.: E1A mediated paclitaxel sensitization in Her 2 Neu overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000, 6:250–259. This study utilizes our knowledge of pathogenesis and examines a novel approach to overcome chemoresistance.

    PubMed  CAS  Google Scholar 

  35. Holmberg LA, Oparin DV, Gooley T, et al.: Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000, 25:1233–1241.

    Article  PubMed  CAS  Google Scholar 

  36. Santin AD, Hermonat PL, Ravaggi A, et al.: In vitro induction of tumor specific human lymphocyte antigen class I-restricted CD 8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000, 183:601–609.

    Article  PubMed  CAS  Google Scholar 

  37. Schultes BC, Zhang C, Xue LY, et al.: Immunotherapy of human ovarian carcinoma with OVAREX Mab-B43.13 in a human PBLSCID/ BG mouse model. Hybridoma 1999, 18:47–55.

    Article  PubMed  CAS  Google Scholar 

  38. Berek J, Ehlen T, Gordon A, et al.: Interim analysis of a double blind study of ovarex mAb B43.13 versus placebo in patients with ovarian cancer [abstract]. Proc ASCO 2001, 20:210a.

    Google Scholar 

  39. Molpus KL, Hamblin MR, Rizvi I, Hasan T: Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol 2000, 76:397–404.

    Article  PubMed  CAS  Google Scholar 

  40. Finkler N, Gordon A, Crozier, et al.: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract]. Proc ASCO 2001, 20:831. Novel agents such as EGFR-TK antagonists need to be studied in ovarian cancer in addition to cytotoxic chemotherapy in order to improve outcomes in this devastating cancer.

    Google Scholar 

  41. Garcia A, Gordon M, Markman M, et al.: Phase I/II trial of IM862, a novel immunomodulator with anti-angiogenic activity in patients with recurrent ovarian cancer [abstract]. Proc ASCO 2001, 20:840.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 1st Street SW, 55905, Rochester, MN, USA

    Prema P. Peethambaram MD & Harry J. Long MD

Authors
  1. Prema P. Peethambaram MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harry J. Long MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peethambaram, P.P., Long, H.J. Second-line and subsequent therapy for ovarian carcinoma. Curr Oncol Rep 4, 159–164 (2002). https://doi.org/10.1007/s11912-002-0077-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0077-0

Keywords

Search

Navigation